Testing the Efficacy of Multi-day Interruptions in Sedentary Behaviors on Metabolic, Cognitive, and Affective Outcomes in Youth at Risk for Type 2 Diabetes

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The overall objective of this in-lab randomized controlled trial is to test the efficacy of multi-day interruptions in sedentary behavior vs. single bouts of sustained exercise on metabolic, cognitive, affective, and cardiac autonomic nervous system responses in children with overweight and obesity who are at risk for type 2 diabetes. The use of continuous glucose monitoring will provide insight into the daily and cumulative metabolic effects of each condition that have thus far not been studied. In-lab studies demonstrating sustained efficacy of this approach in ameliorating negative effects of sedentary behaviors in children are necessary for the optimization of field-based interventions. Given the lack of success of interventions to prevent obesity-related diseases and increasing rates of type 2 diabetes in children and its related healthcare costs, this study addresses a critical public health need by testing of novel intervention strategies to reduce obesity-related diseases in children with overweight and obesity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Maximum Age: 11
Healthy Volunteers: t
View:

• Age 8-11 years-old

• Good general health

• BMI≥85th percentile

Locations
United States
California
Britni Ryan Belcher, PhD, MPH
RECRUITING
Los Angeles
Time Frame
Start Date: 2022-03-01
Estimated Completion Date: 2026-08-31
Participants
Target number of participants: 188
Treatments
No_intervention: SIT
Continuous sitting for 3 hours
Experimental: SIT+WALK
Interrupt sitting with 3-minutes of moderate-intensity walking every 30 minutes for 3 hours
Experimental: EX
Perform 18 consecutive minutes of moderate-intensity walking, then sit for the remaining time
Related Therapeutic Areas
Sponsors
Leads: University of Southern California
Collaborators: Dana-Farber Cancer Institute

This content was sourced from clinicaltrials.gov